Your browser doesn't support javascript.
loading
Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study.
Goy, A; Bernstein, S H; Kahl, B S; Djulbegovic, B; Robertson, M J; de Vos, S; Epner, E; Krishnan, A; Leonard, J P; Lonial, S; Nasta, S; O'Connor, O A; Shi, H; Boral, A L; Fisher, R I.
Affiliation
  • Goy A; The Cancer Center at Hackensack University Medical Center, Hackensack, NJ 07601, USA. agoy@humed.com
Ann Oncol ; 20(3): 520-5, 2009 Mar.
Article in En | MEDLINE | ID: mdl-19074748
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pyrazines / Boronic Acids / Lymphoma, Mantle-Cell / Antineoplastic Agents Type of study: Clinical_trials Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2009 Document type: Article Affiliation country: Estados Unidos Country of publication: Reino Unido
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pyrazines / Boronic Acids / Lymphoma, Mantle-Cell / Antineoplastic Agents Type of study: Clinical_trials Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2009 Document type: Article Affiliation country: Estados Unidos Country of publication: Reino Unido